Legend Biotech Corp
LEGNNasdaq
$22.26
↓ -2.0%Jul 17 close · end-of-day
Price
1Y↓ -44.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Legend Biotech Corporation engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for gastric cancer and T cell lymphoma.
- CEO
- Ying Huang
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,070
- Headquarters
- New Jersey
- Website
- legendbiotech.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Casey Patrick John | Sale | 6,000 | $14.80 | $88,800.00 | filing |
| 2026-06-30 | Huang Ying· Chief Executive Officer | Gift | 3,382 | $0.00 | $0.00 | filing |
| 2026-06-25 | Huang Ying· Chief Executive Officer | Sale | 5,566 | $14.78 | $82,265.48 | filing |
| 2026-03-25 | Huang Ying· Chief Executive Officer | Sale | 9,936 | $8.77 | $87,138.72 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.